Tags

Type your tag names separated by a space and hit enter

Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.
Psychopharmacology (Berl). 2020 Apr; 237(4):1121-1130.P

Abstract

RATIONALE

Stress is a risk factor for psychosis and treatments which mitigate its harmful effects are needed. Cannabidiol (CBD) has antipsychotic and anxiolytic effects.

OBJECTIVES

We investigated whether CBD would normalise the neuroendocrine and anxiety responses to stress in clinical high risk for psychosis (CHR) patients.

METHODS

Thirty-two CHR patients and 26 healthy controls (HC) took part in the Trier Social Stress Test (TSST) and their serum cortisol, anxiety and stress associated with public speaking were estimated. Half of the CHR participants were on 600 mg/day of CBD (CHR-CBD) and half were on placebo (CHR-P) for 1 week.

RESULTS

One-way analysis of variance (ANOVA) revealed a significant effect of group (HC, CHR-P, CHR-CBD (p = .005) on cortisol reactivity as well as a significant (p = .003) linear decrease. The change in cortisol associated with experimental stress exposure was greatest in HC controls and least in CHR-P patients, with CHR-CBD patients exhibiting an intermediate response. Planned contrasts revealed that the cortisol reactivity was significantly different in HC compared with CHR-P (p = .003), and in HC compared with CHR-CBD (p = .014), but was not different between CHR-P and CHR-CBD (p = .70). Across the participant groups (CHR-P, CHR-CBD and HC), changes in anxiety and experience of public speaking stress (all p's < .02) were greatest in the CHR-P and least in the HC, with CHR-CBD participants demonstrating an intermediate level of change.

CONCLUSIONS

Our findings show that it is worthwhile to design further well powered studies which investigate whether CBD may be used to affect cortisol response in clinical high risk for psychosis patients and any effect this may have on symptoms.

Authors+Show Affiliations

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry, Policlinico "G. B. Rossi", University of Verona, P.le L.A. Scuro 10, 37134, Verona, Italy.Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK. Department of Psychiatry, University Medical Centre Utrecht Brain Centre, Utrecht University, Utrecht, The Netherlands.Department of Psychology, IoPPN, King's College London, London, PO Box 77, UK. National Institute for Health Research, Biomedical Research Centre, London, UK.National Institute for Health Research, Biomedical Research Centre, London, UK. Department of Psychological Medicine, IoPPN, King's College London, London, UK.Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK. National Institute for Health Research, Biomedical Research Centre, London, UK.Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK. sagnik.2.bhattacharyya@kcl.ac.uk. National Institute for Health Research, Biomedical Research Centre, London, UK. sagnik.2.bhattacharyya@kcl.ac.uk.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

31915861

Citation

Appiah-Kusi, E, et al. "Effects of Short-term Cannabidiol Treatment On Response to Social Stress in Subjects at Clinical High Risk of Developing Psychosis." Psychopharmacology, vol. 237, no. 4, 2020, pp. 1121-1130.
Appiah-Kusi E, Petros N, Wilson R, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology (Berl). 2020;237(4):1121-1130.
Appiah-Kusi, E., Petros, N., Wilson, R., Colizzi, M., Bossong, M. G., Valmaggia, L., Mondelli, V., McGuire, P., & Bhattacharyya, S. (2020). Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology, 237(4), 1121-1130. https://doi.org/10.1007/s00213-019-05442-6
Appiah-Kusi E, et al. Effects of Short-term Cannabidiol Treatment On Response to Social Stress in Subjects at Clinical High Risk of Developing Psychosis. Psychopharmacology (Berl). 2020;237(4):1121-1130. PubMed PMID: 31915861.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. AU - Appiah-Kusi,E, AU - Petros,N, AU - Wilson,R, AU - Colizzi,M, AU - Bossong,M G, AU - Valmaggia,L, AU - Mondelli,V, AU - McGuire,P, AU - Bhattacharyya,S, Y1 - 2020/01/08/ PY - 2019/02/18/received PY - 2019/12/27/accepted PY - 2020/1/10/pubmed PY - 2020/9/15/medline PY - 2020/1/10/entrez KW - Cannabidiol KW - Psychosis KW - Trier Social Stress Test KW - Ultra-high risk SP - 1121 EP - 1130 JF - Psychopharmacology JO - Psychopharmacology (Berl) VL - 237 IS - 4 N2 - RATIONALE: Stress is a risk factor for psychosis and treatments which mitigate its harmful effects are needed. Cannabidiol (CBD) has antipsychotic and anxiolytic effects. OBJECTIVES: We investigated whether CBD would normalise the neuroendocrine and anxiety responses to stress in clinical high risk for psychosis (CHR) patients. METHODS: Thirty-two CHR patients and 26 healthy controls (HC) took part in the Trier Social Stress Test (TSST) and their serum cortisol, anxiety and stress associated with public speaking were estimated. Half of the CHR participants were on 600 mg/day of CBD (CHR-CBD) and half were on placebo (CHR-P) for 1 week. RESULTS: One-way analysis of variance (ANOVA) revealed a significant effect of group (HC, CHR-P, CHR-CBD (p = .005) on cortisol reactivity as well as a significant (p = .003) linear decrease. The change in cortisol associated with experimental stress exposure was greatest in HC controls and least in CHR-P patients, with CHR-CBD patients exhibiting an intermediate response. Planned contrasts revealed that the cortisol reactivity was significantly different in HC compared with CHR-P (p = .003), and in HC compared with CHR-CBD (p = .014), but was not different between CHR-P and CHR-CBD (p = .70). Across the participant groups (CHR-P, CHR-CBD and HC), changes in anxiety and experience of public speaking stress (all p's < .02) were greatest in the CHR-P and least in the HC, with CHR-CBD participants demonstrating an intermediate level of change. CONCLUSIONS: Our findings show that it is worthwhile to design further well powered studies which investigate whether CBD may be used to affect cortisol response in clinical high risk for psychosis patients and any effect this may have on symptoms. SN - 1432-2072 UR - https://www.unboundmedicine.com/medline/citation/31915861/Effects_of_short_term_cannabidiol_treatment_on_response_to_social_stress_in_subjects_at_clinical_high_risk_of_developing_psychosis_ L2 - https://dx.doi.org/10.1007/s00213-019-05442-6 DB - PRIME DP - Unbound Medicine ER -